Osivax raised €9.5M in a Series B round in Mar 2025. The company is based in Lyon, France. Investors in the round: Meiji Seika Pharma. Data as of 7 Aug 2026.
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
